There are ways practices can take advantage of the delay of Oncology Care First (OCF) to continue learning from their experience in Oncology Care Model (OCM), said Mike Fazio, of Archway Health.
There are ways practices can take advantage of the delay of Oncology Care First (OCF) to continue learning from their experience in Oncology Care Model (OCM), said Mike Fazio, senior vice president of Client Services at Archway Health.
Transcript
With Oncology Care First being delayed, are there ways that practices can take advantage of that delay to take what they've learned while participating in Oncology Care Model to make a smoother transition and be successful?
It's been, I think, positively received, at least from the customers that we support for OCM, that the program has been extended a year. So, that anxiety of a new model, and what that will look like is now pushed back. And so, practices can still use the data that they're getting from CMS for OCM to figure out how to refine their model, what works and what doesn't. It is still a pilot, so that pilot continues for another year.
So, using data to improve quality, which is a component of OCM, there's still time to do that. So, things like is your symptom management tool, really reducing ED [emergency department] visits and hospitalizations? You have more time to look at that and to tweak your model. Introducing palliative care early to increase hospice use at end of life—are those processes working or not? And what can you change? And the same thing with supportive therapies and in using biosimilars. So, are those taking an effect, and can we measure those results? We have more time in data to see are those changes happening and are those levers being moved so that you can address changes in the model?
So, I guess you could use the extra time to refine your model and see what's working and what isn't. So that when OCF is announced, and if it's the right program for you, you can have a better sense of what really worked in OCM. So just given the more time that you have.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More